Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Medical uses == Abatacept is used to treat adults with moderate to severe rheumatoid arthritis (RA) as a second-line agent, and as a first-line agent for people whose RA is severe and rapidly progressing. It also used to treat psoriatic arthritis and juvenile idiopathic arthritis.
1996: Rozman Jusoh and Razali Mat Zin, both Malaysian odd-job labourers, hanged on 12 April 1996 for trafficking a total of nearly 2 kg of marijuana. 1999: Chua Gin Boon, hanged on 25 June 1999 for trafficking 60g of heroin. 2003: Vignes Mourthi and Moorthy Angappan, the two Malaysians hanged on 26 September 2003 for smuggling 27.65g of diamorphine. 2004: Yen May Woen, a Singaporean hairdresser hanged on 19 March 2004 for trafficking 30 grams of pure heroin 2005: Shanmugam Murugesu, a Singaporean former athlete and military man hanged on 13 May 2005 for smuggling 1 kg of cannabis. 2005: Nguyen Tuong-van, an Australian hanged on 2 December 2005 for smuggling 396.2 grams of diamorphine (pure heroin). 2007: Iwuchukwu Amara Tochi and Okeke Nelson Malachy, two Nigerians hanged on 26 January 2007 for smuggling diamorphine. 2022: Abdul Kahar Othman, a Singaporean who was executed on 30 March 2022 for trafficking 66.77g of diamorphine in 2010. Abdul Kahar was a first convict to be hanged during COVID Pandemic. 2022: Nagaenthran K.
Using cells in culture Pre-treating cells in a hypotonic solution, which swells them and spreads the chromosomes Arresting mitosis in metaphase by a solution of colchicine Squashing the preparation on the slide forcing the chromosomes into a single plane Cutting up a photomicrograph and arranging the result into an indisputable karyogram. It took until 1956 for it to be generally accepted that the karyotype of man included only 46 chromosomes. The great apes have 48 chromosomes. Human chromosome 2 was formed by a merger of ancestral chromosomes, reducing the number.
Sources: en.wikipedia.org
=== Shellworlds === Shellworlds are introduced in Matter, and consist of multilayered levels of concentric spheres in four dimensions held up by countless titanic interior towers. Their extra dimensional characteristics render some products of Culture technology too dangerous to use and yet others ineffective, notably access to hyperspace. About 4000 were built millions of years ago as vast machines intended to cast a forcefield around the whole of the galaxy for unknown purposes; less than half of those remain at the time of Matter, many having been destroyed by a departed species known as the Iln. The species that developed this technology, known as the Veil or the Involucra, are now lost, and many of the remaining shellworlds have become inhabited, often by many different species throughout their varying levels. Many still hold deadly secret defence mechanisms, often leading to great danger for their new inhabitants, giving them one of their other nicknames: Slaughter Worlds.
== Career == As noted in his obituary in Clinical Chemistry, Masahide "graduated from Yamaguchi Medical School in 1961. During 1965, he served as an internist for the Hiroshima Atomic Bomb Casualty Committee. Several years later, in 1967, he was appointed the Chief of the Clinical Chemistry Department at Kawasaki Hospital. In 1970, he did a fellowship in the United States at the Michael Reese Hospital in Chicago, IL, which gave him exposure to the US medical system. Two years later he became an Assistant Professor of Internal Medicine at Kawasaki Medical School and rose quickly in the academic ranks to become a Full Professor of Laboratory Diagnosis in 1976 and, ultimately, Vice President of Kawasaki Paramedical College." He was appointed Professor and Director of the Department of the Clinical Laboratory at Kochi Medical School, Kochi, Japan in 1981. There, he developed his automation system. Masahide published many papers between 1981 and 1999, the most notable of which was a monograph on laboratory automation sponsored by the A&T Corporation.
Dermorphin is a hepta-peptide first isolated from the skin of South American frogs belonging to the genus Phyllomedusa. The peptide is an agonist with high potency and selectivity to mu opioid receptors. Dermorphin is about 30–40 times more potent than morphine. The amino acid sequence of dermorphin is H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2. Dermorphin is not found in humans or other mammals and similar D-amino acid containing peptides have only been found in bacteria, amphibians, and molluscs. Dermorphin appears to be made via the posttranslational modification of a precursor peptide by an amino acid isomerase. This unusual process is needed because the D-alanine in this peptide is not part of the standard genetic code.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.